TY - CHAP M1 - Book, Section TI - Bastilimab plus zalifrelimab showed promising clinical and safety response for the treatment of refractory cervical cancer A1 - Park, Jamie A1 - Chan, Samuel Y1 - 2015 N1 - T2 - 2 Minute Medicine AB - SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=579731 ER -